A Safety Study of NNZ-2566 in Patients With Rett Syndrome
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the
treatment of Rett Syndrome in adolescent and adult females.
Phase:
Phase 2
Details
Lead Sponsor:
Neuren Pharmaceuticals Limited
Collaborators:
Baylor College of Medicine International Rett Syndrome Foundation Texas Children's Hospital